Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Merck’s CETP inhibitor seems to have very low chances of success after Eli Lilly’s similar drug failed in its late stages
Merck’s CETP inhibitor seems to have very low chances of success after Eli Lilly’s similar drug failed in its late stages
Merck’s CETP inhibitor seems to have very low chances of success after Eli Lilly’s similar drug failed in its late stages
Submitted by
admin
on October 15, 2015 - 9:41am
Source:
Bidness, ETC
News Tags:
Merck
Eli Lilly
CETP inhibitors
Anacetrapib
evacetrapib
Headline:
Merck’s CETP inhibitor seems to have very low chances of success after Eli Lilly’s similar drug failed in its late stages
Do Not Allow Advertisers to Use My Personal information
